Aggressive lipid-lowering benefits bypass patients
reuters.com     May 21, 2008            

NEW YORK (Reuters Health) - In patients who have had heart bypass surgery, taking the cholesterol-lowering drug Lipitor at a dose of 80 milligrams per day, rather than 10 milligrams per day, can markedly improve outcomes, new research shows. Major heart-related "events" fell by 27 percent and the... [read full story]                    


View all news articles about*:
Aid Care Cholesterol Diet Drugs General Health Hospital Hospitals Medicines Patients Pharmaceuticals Remedies Surgery
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Statin Therapy Is Underused For Atherosclerosis Patients

medicalnewstoday.com     1 hr ago          

Statins, a group of drugs used to lower cholesterol levels in people with or at risk of having cardiovascular disease, should be used more frequently to combat the adverse cardiovascular outcomes from atherosclerosis,...                    

comments

Cholesterol drugs' cancer risk in spotlight

ibtimes.com     17 hrs ago   1 related          

TRENTON, N.J. - New data on whether the popular cholesterol drugs Zetia and Vytorin increase risk of cancer will be one of the highlights of a huge European conference of heart specialists opening Saturday. The drugs'...                    

comments

Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before...

yahoo.com     23 hrs ago   2 related          

NEW YORK----Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company's favor in challenges to two of its patents covering atorvastatin, the active ingredient in...                    

comments

Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before...

businesswire.com     23 hrs ago   3 related          

NEW YORK-- --Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in challenges to two of its patents covering atorvastatin, the active ingredient in...                    

comments